by secretome | Sep 17, 2024 | Journals
DALLAS, Sept. 17, 2024 /PRNewswire/ — HEST Investments, a Dallas-based venture capital family office renowned for its focus on innovative and bleeding edge ventures, proudly announces its successful SPV (Special Purpose Vehicle) of a $1.8 million investment...
by secretome | Jul 18, 2024 | Journals, News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors. “Margot’s unparalleled...
by Sudhish Sharma | Jun 17, 2022 | Journals, Uncategorized
Abstract Gunasekaran et al demonstrate that human neonatal Mesenchymal Stem Cells (nMSCs) evade from macrophage mediated phagocytosis via increased CD47 expression and to promote functional recovery by secretion of exosomes and independent cytokines. The increased...
by Sudhish Sharma | May 22, 2019 | Journals, Uncategorized
Abstract The stem cell field is hindered by its inability to noninvasively monitor transplanted cells within the target organ in a repeatable, time-sensitive, and condition-specific manner. We hypothesized that quantifying and characterizing transplanted cell–derived...
by Sudhish Sharma | Jul 6, 2018 | Journals, Uncategorized
Abstract Hypoplastic left heart syndrome is a type of congenital heart disease characterized by underdevelopment of the left ventricle, outflow tract, and aorta. The condition is fatal if aggressive palliative operations are not undertaken, but even after the complete...
by Sudhish Sharma | Apr 2, 2018 | Journals, Uncategorized
Abstract One of the most complex forms of congenital heart disease (CHD) involving single ventricle physiology is hypoplastic left heart syndrome (HLHS), characterized by underdevelopment of the left ventricle (LV), mitral and aortic valves, and narrowing of the...
